Catalyst Pharmaceuticals (CPRX) Total Current Liabilities (2010 - 2026)

Catalyst Pharmaceuticals (CPRX) has 17 years of Total Current Liabilities data on file, last reported at $132.4 million in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities rose 18.58% year-over-year to $132.4 million; the trailing twelve-month figure through Mar 2026 stood at $132.4 million (up 18.58% YoY), and the FY2025 full-year result was $147.2 million, up 21.94% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $132.4 million, down from $147.2 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $147.2 million in Q4 2025 and bottomed at $22.5 million in Q2 2022.
• The 5-year median for Total Current Liabilities is $79.6 million (2024), against an average of $83.6 million.
• The widest annual swing landed in 2023, when Total Current Liabilities jumped 147.23%; it then climbed 18.58% in 2026.
• A 5-year view of Total Current Liabilities shows it stood at $57.6 million in 2022, then jumped by 32.08% to $76.1 million in 2023, then surged by 58.66% to $120.7 million in 2024, then advanced by 21.94% to $147.2 million in 2025, then decreased by 10.03% to $132.4 million in 2026.
• The last three Total Current Liabilities figures came in at $132.4 million (Q1 2026), $147.2 million (Q4 2025), and $128.7 million (Q3 2025), per Business Quant data.

Peer Comparison